

Phase 2 Study for Lyme Disease Vaccine Candidate Begins

Valneva and Pfizer announced that they have initiated a Phase 2 study for their Lyme disease vaccine candidate. This new study builds on previous studies, including new dose regimens as well as being the first clinical study to include children between the ages 5-17 years.